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Background. Immune responses are complex traits influenced by genetic and environmental factors. We pre-
viously reported that genetic factors control early antibody responses to vaccines in Gambian infants. For the
present study, we evaluated the determinants of the memory phase of immunoglobulin G (IgG) responses.
Methods. Antibody responses to tetanus toxoid (TT), measles vaccines, and environmental antigens (total IgG
levels) were measured in 210 Gambian twin pairs recruited at birth. Intrapair correlations for monozygous and
dizygous pairs were compared to estimate the environmental and genetic components of variations in response.
Results. In contrast to antibody responses measured in infants at age 5 months, 1 month after immunization,
no significant contribution of genetic factors to anti-TT antibody and total IgG levels was detected at age 12
months. Genetic factors controlled measles antibody responses in 12-month-old infants, which indicates that the
increasing influence of environmental determinants on anti-TT responses was not related to the older age of the
children but, rather, to the time elapsed since immunization. Environmental factors also predominantly controlled
affinity maturation and the production of high-avidity antibodies to TT.
Conclusions. Genetic determinants control the early phase of the vaccine antibody response in Gambian infants,
whereas environmental determinants predominantly influence antibody persistence and avidity maturation.
The immunization of young infants is required to pre-
vent infectious diseases in early life, but its effectiveness
is impeded by the immaturity of the infant immune
system [1–3]. Young infants produce significantly lower
antibody responses to T cell–independent and most T
cell–dependent vaccine antigens than do older children
or adults [4–9]. Therefore, the induction of protective
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immunity in early life generally requires the adminis-
tration of multiple doses of primary vaccine. Unfor-
tunately, antibody responses to vaccines administered
during the first year of life are of shorter duration than
those elicited in adults, even after several doses of vac-
cine. This may result in short-term protection and re-
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quire the administration of booster doses of vaccines as soon
as the second year of life [10–14].
The capacity of young infants to develop high-avidity anti-
body responses to vaccines has not yet been fully characterized.
Avidity maturation results from the combined effects of somatic
hypermutation and a process of antigen-driven selection [15–
17]. Somatic mutations in immunoglobulin genes mature dur-
ing the first year of life, and evidence for selection has been
observed only after 6 months of age [18, 19]. After Neisseria
meningitidis infection, infants produce antibodies of lower avid-
ity than those produced by older children [20]. Similarly, fewer
mutations have been observed in immunoglobulin genes of B
cells harvested after rotavirus infection in infants, compared
with adults [21]. In contrast, high-avidity antibodies are in-
duced by the immunization of infants with polysaccharide con-
jugate vaccines [22–25], and an adult-like process of avidity
maturation to complex vaccine antigens has been demonstrated
in murine models of neonatal immunization [26].
Immune responses are inherited as complex quantitative
traits, with variation resulting from genetic and environmental
factors. Twin studies are a powerful method with which to
quantify the relative contribution of genetic and environmental
factors to any phenotype. Genetic effects are revealed if the con-
cordance for a phenotype is higher within monozygous (MZ)
twin pairs, who are genetically identical, than within dizygous
(DZ) twin pairs, who share, on average, 50% of their genes. We
previously reported that host genes play a predominant role in
the control of early primary antibody responses to vaccine an-
tigens in Gambian infants [27]. The present analysis was un-
dertaken in the same study population, for the evaluation of the
respective role of genetic and environmental determinants in (1)
long-term persistence and (2) the avidity maturation of antibody
responses in infants.
We assessed antibody responses to a protein antigen, tetanus
toxoid (TT), in a population of Gambian infant twins immunized
at 2, 3, and 4 months of age [27]. We compared titers and the
avidity of anti-TT antibodies present during the early (5 months)
and late (12 months) phase of the vaccine response in MZ and
DZ twins, to define whether these were influenced by mainly
genetic or environmental determinants. We selected TT because
it is sufficiently immunogenic for antibody responses to persist
in most 12-month-old infants, in contrast to diphtheria toxoid
(data not shown). In addition, environmental exposure to Clos-
tridium tetanii does not influence TT-specific antibodies [28], in
contrast to the likely exposure of Gambian infants to pertussis,
Haemophilus influenzae type b, or hepatitis B virus. Between 5
and 12 months of age, the persistence and avidity maturation of
TT-specific antibodies is therefore driven solely by the late de-
velopment of the primary immune response and/or by exposure
to non–TT-specific factors. The antibody response to measles
vaccine given at 9 months of age was also assessed when infants
were 12 months old, to allow the distinction between the influ-
ence of the age at sampling and of the postimmunization period
on the factors controlling infant antibody responses. In devel-
oping countries, immunization with the live attenuated measles
vaccine is recommended at age 9 months, to avoid the inhibitory
effect of maternal antibodies [29]. Studies have suggested that
immunization during infancy could be associated with a more-
rapid waning of anti-measles antibodies and with an increased
risk of disease during the teen years [11, 13, 14]. Vaccine failure
is observed in 2%–5% of measles-vaccine recipients, and this
may involve genetic factors [29, 30]. Finally, we measured total
serum IgG levels, to compare the influence of genetic and en-
vironmental factors on nonvaccine antigens.
SUBJECTS, MATERIALS, AND METHODS
Study population. The study was conducted in The Gambia
and was approved by the Gambian government and the Medical
Research Council Ethics Committee. Twin pairs were enrolled
at birth at the Royal Victoria Hospital (the referral hospital in
the capital, Banjul) or at 1 of 2 health centers (Serrekunda and
Fajikunda) in the same district. Exclusion criteria were death
of 1 or both twins at or shortly after birth, residence outside
the study area, and bacille Calmette-Gue´rin (BCG) vaccine hav-
ing been administered to the infants in the hospital before their
enrollment in the study. Informed consent was obtained from
parents, and demographic data—including ethnicity, family his-
tory, and maternal health during pregnancy—were collected by
interview. Enrolled twins were examined within 3 days after birth,
and birth weight, length, and gestational age [31] were recorded.
Twins were monitored monthly until they were 5 months old
and then when they were 9 and 12 months old; they were vac-
cinated in accordance with the Expanded Programme on Im-
munization schedule (World Health Organisation). BCG vaccine
(0.05 mL; Statens Serum Institut) was administered intradermally
at birth (or at age 1 month if either twin weighed !2.5 kg). A
combination diphtheria, tetanus, and whole-cell pertussis vaccine
(Aventis Pasteur) in which H. influenzae type b vaccine (ActHIB;
Aventis Pasteur) was diluted was administered intramuscularly
(im) at age 2, 3, and 4 months. Measles vaccine (Aventis Pasteur)
was administered im at age 9 months. Blood samples were col-
lected at birth (umbilical cord blood) and when infants were 2,
5, and 12 months old.
Zygosity determination. The zygosity of same-sex pairs
was determined genetically by typing 10 microsatellite markers,
as described elsewhere [32]. Twin pairs with identical genotypes
for all markers were classified as being MZ.
Antibody assays. Concentrations of total serum IgG and
antibody to TT were measured as described elsewhere [27]. The
avidity (defined for complex antigens as the antigen binding
capacity resulting from the addition of all epitope-specific af-
finities) of TT-specific IgG antibodies was determined by ELISA
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Table 1. Antibody response to tetanus toxoid (TT) and measles vaccine and total IgG concentrations in monozygous (MZ) and dizygous
(DZ) twins.
Measurement Age, months
MZ DZ
PbNo.a Geometric mean (95% CI) No.a Geometric mean (95% CI)
Anti-TT antibody concentration, mIU/mL 5 100 3236 (2575–4065) 320 3329 (2967–3736) .87
12 86 465 (375–578) 247 455 (396–523) .89
IgG antibody concentration, mg/mL 5 100 8.76 (8.19–9.37) 319 8.97 (8.58–9.37) .66
12 88 11.36 (10.6–12.2) 258 10.72 (10.3–11.2) .29
Anti-measles antibody concentration, mIU/mL 12 92 1111 (879–1406) 244 1146 (987–1330) .86
NOTE. CI, confidence interval.
a No. of individual twins in whom antibody responses were successfully measured.
b Obtained by linear regression of log-normal antibody response, with zygosity as the explanatory variable, adjusting for clustering of response within twin pairs.
elution using ammonium thiocyanate (NH4SCN) as a chao-
tropic agent, as described elsewhere [26]. Results are expressed
as the avidity index (AI), the concentration of thiocyanate re-
quired to elute 50% of antibodies [26], and as proportions of
high-avidity (% HA) antibodies, which was defined for this an-
tigen as the proportion of antibody molecules that remain bound
to the plates at NH4SCN concentrations 13 mol/L. Concentra-
tions of antibody to measles vaccine were determined by hem-
agglutination-inhibition assay [33]. Antibody concentrations be-
low the assay cutoff were arbitrarily given a value of one-half the
cutoff value for the determination of geometric mean titers.
Statistical analysis. Differences in logarithmic antibody re-
sponses between MZ and DZ twin pairs were analyzed with Stata
software (version 8.1; StataCorp), using linear regression with
adjustment for the nonindependence of twin pairs. Intra–twin
pair correlations were calculated separately for MZ and DZ twins,
using Pearson’s correlation coefficient. Heritability (the genetic
contribution to the total phenotypic variation in the population)
was estimated using structural equation modeling, implemented
in Mx GUI (version 1.3.65) [34, 35]. Briefly, the total population
variance observed for a given phenotype results from the sum
of (1) genetic variance, (2) common environmental variance
caused by the effects of environmental factors shared within
families, and (3) unique environmental variance specific to each
individual. Genetic factors increase correlations within MZ twin
pairs, common environmental factors increase intrapair corre-
lations for both MZ and DZ twin pairs, and unique environ-
mental factors will decrease intrapair correlations for both MZ
and DZ twin pairs.
We compared models that allowed for additive genetic (A),
common environmental (C), and unique environmental (E)
contributions to phenotypic variation. The results below pre-
sent heritability under the ACE model—unless the AE model
fitted as well as the ACE model ( )—generally reflected inP 1 .1
lower DZ correlations, and the CE model fitted significantly
worse than the ACE model ( ). In this case, heritabilityP ! .1
under the AE model is shown. Similarly, the CE model was the
final model if it fitted as well as the ACE model ( ) andP 1 .1
the AE model fitted significantly worse than the ACE model
( ). Point estimates and 95% confidence intervals (CIs) forP ! .1
heritability under the final model are presented.
RESULTS
A total of 560 twin pairs were identified between March 1998
and May 2000; of these, 345 (62%) were eligible for the study.
The reasons for ineligibility were as follows: death of 1 or both
twins at or shortly after birth (92), residence outside the study
area (101), and BCG vaccine having been administered in the
hospital before enrollment (22). Of the 345 eligible pairs, 297
(86%) were enrolled. Reasons for nonenrollment were refusal
(22) and no traceable address (26). All twin pairs were breast-
fed and lived together for the duration of the study. Of the 297
twin pairs enrolled, zygosity data were available for 217 (59 MZ
and 158 DZ). Of these, 179 pairs (43 MZ and 136 DZ) were
studied at age 2 months, 210 pairs (50 MZ and 160 DZ) were
studied at age 5 months, and 175 pairs (46 MZ and 129 DZ)
were studied at age 12 months. There were no significant dif-
ferences in sex, ethnic group, gestational age, birth weight, or
birth center between MZ and DZ twin pairs. Parity was higher
in DZ than in MZ twin pairs (4.5 vs. 3.6; ).Pp .02
Environmental determinants influence the persistence of
anti-TT antibodies. Figure 1 (top) shows the geometric mean
anti-TT antibody levels in a subgroup of 259 infant twins who
could be tested at ages 2, 5, and 12 months. The administration
of TT vaccine at ages 2, 3, and 4 months induced high levels
of anti-TT antibodies, as measured at age 5 months. Between
ages 5 and 12 months, anti-TT antibody levels decreased 7-fold.
The levels of anti-TT antibodies at ages 5 and 12 months were
similar in MZ and DZ twins (table 1). Intrapair correlations of
anti-TT antibody levels within MZ and DZ twin pairs and her-
itability are shown in table 2. As reported elsewhere [27], the
levels of anti-TT antibodies at age 5 months were significantly
more correlated within the MZ twin pairs than within the DZ
twin pairs, and the final model included additive genetic and
environmental factors. The heritability of anti-TT antibodies at
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Table 2. Pairwise correlations and heritabilities for antibody
responses to tetanus toxoid (TT) and measles vaccine and total
IgG concentrations.
Antibody
Age,
months
r (no.)
Heritability
(95% CI), %
Final
modelMZ DZ
Anti-TT 5 0.83 (50) 0.56 (160) 45 (18–70) ACE
12 0.67 (43) 0.56 (123) 33 (0–66) ACE
IgG 5 0.74 (50) 0.54 (159) 79 (69–86) AEa
12 0.66 (44) 0.66 (129) 0 CEb
Anti-measles 12 0.74 (45) 0.45 (123) 62 (27–83) ACE
NOTE. Significant heritabilities are given in bold type. ACE, additive genetic
plus common environmental plus unique environmental model; AE, additive
genetic plus unique environmental model; CE, common environmental plus
unique environmental model; CI, confidence interval; DZ, dizygous; MZ,
monozygous.
a Heritability under the ACE model, 66% (95% CI, 35%–85%).
b Heritability under the ACE model, 0% (95% CI, 0%–25%).
Figure 1. Antibody response to tetanus toxoid (TT) in infants. Infant
twins were immunized with TT at 2, 3, and 4 months of age. Anti-TT
antibody levels were measured by ELISA when infants were 2, 5, and 12
months old. Antibody avidity was measured when infants were 5 and 12
months old by ELISA elution with thiocyanate as a chaotropic agent. The
avidity index (AI) represents the concentration of thiocyanate required to
elute 50% of the antibodies, and the percentage of high-avidity (% HA)
antibodies is the proportion of antibody molecules bound to the plates at
thiocyanate concentrations 13 mol/L. The figure shows geometric mean
and 95% confidence intervals of antibody responses measured in a sub-
group of infant twin pairs from whom antibody and antibody data were
available for 2, 5, and 12 months of age. * vs. age 2 months;P ! .001
** vs. age 5 months. ND, not done.P ! .001
age 5 months was statistically significant (45% [95% CI, 18%–
70%]) (table 2). At age 12 months, however, the correlation of
anti-TT antibody levels had decreased in MZ twin pairs, and no
significant influence of genetic determinants was detected. To
verify that this difference was not related to the smaller group
studied at age 12 months, heritability of antibody titers at age 5
months was estimated in the subgroup of MZ and DZ twin pairs
for whom data were available at age 12 months. In this subgroup
of infants, anti-TT antibody levels at age 5 months were signif-
icantly more correlated within MZ twin pairs ( ) thanrp 0.85
within DZ twin pairs ( ), which resulted in significantrp 0.61
heritability (36% [95% CI, 9%–63%]).
Predominant influence of environmental determinants on
total IgG levels at age 12 months. To evaluate whether the
predominant influence of environmental determinants in the
control of anti-TT antibody responses at age 12 months was
specific to TT, the relative influence of genetic versus environ-
mental factors on total IgG concentrations at ages 5 and 12
months was estimated. MZ and DZ twins had similar IgG levels
at ages 5 and 12 months (table 1). As expected, total IgG levels
had increased between ages 5 and 12 months. As reported else-
where [27], a high heritability of total IgG levels was detected at
age 5 months (table 2). In contrast, correlations of IgG levels
were identical in MZ and DZ twin pairs at age 12 months, which
resulted in no detectable heritability, because the final model at
age 12 months included only common and unique environ-
mental factors. Similar estimates of heritability of IgG levels at
ages 5 and 12 months were obtained using the ACE model (table
2). Again, the difference between results at ages 5 and 12 months
was not related to the smaller group studied at age 12 months—
IgG levels measured at age 5 months in MZ and DZ twin pairs
for whom data were available at age 12 months were more cor-
related in MZ ( ) than in DZ ( ) twin pairs, re-rp 0.74 rp 0.54
sulting in significant heritability (36% [95% CI, 3%–65%]).
Thus, genetic determinants significantly influence early infant
antibody responses, whereas environmental factors play a pre-
dominant role at age 12 months.
Predominant role of genetic factors in the primary antibody
response to measles vaccine. The predominant role of envi-
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Table 3. Avidity of anti–tetanus toxoid antibodies in monozygous (MZ) and dizygous (DZ) twins.
Avidity parameter Age, months
MZ DZ
PbNo.a Geometric mean (95% CI) No.a Geometric mean (95% CI)
Avidity index 5 100 1.50 (1.44–1.58) 97 1.52 (1.46–1.59) .77
12 73 2.22 (2.14–2.30) 203 2.23 (2.18–2.27) .89
Proportion of high-avidity antibodies 5 98 0.12 (0.11–0.14) 95 0.12 (0.11–0.14) .97
12 71 0.22 (0.20–0.26) 202 0.24 (0.23–0.25) .49
NOTE. CI, confidence interval.
a No. of individual twins in whom antibody responses were successfully measured.
b Obtained by linear regression of log-normal antibody response with zygosity as the explanatory variable, adjusting for clustering of response within twin pairs.
Table 4. Pairwise correlations and heritabilities for avidity of anti–tetanus toxoid antibodies.
Avidity parameter
Age,
months
r (no.)
Heritability
(95% CI), %
Final
modelMZ DZ
Avidity index 5 0.53 (50) 0.41 (48) 25 (0–67) ACE
12 0.35 (36) 0.39 (101) 0 CEa
Proportion of high-avidity antibodies 5 0.42 (49) 0.39 (46) 20 (0–64) ACE
12 0.58 (35) 0.34 (100) 25 (0–65) ACE
NOTE. ACE, additive genetic plus common environmental plus unique environmental model; CE, common
environmental plus unique environmental model; CI, confidence interval; DZ, dizygous; MZ, monozygous.
a Heritability under the ACE model, 0% (95% CI, 0%–39%).
ronmental determinants in anti-TT and total IgG responses ob-
served at age 12 months could be related to the increasing age
of the infants and/or to the time elapsed after immunization. To
evaluate the influence of age on the relative role of genetic and
environmental factors, we estimated the heritability of the an-
tibody response to measles vaccine, administered at age 9 months,
in 12-month-old infants. MZ and DZ twins showed similar an-
tibody responses to measles vaccine (table 1). As shown in table
2, correlations of anti-measles antibody levels were higher within
MZ than within DZ twin pairs, resulting in significant heritability
(62% [95% CI, 27%–83%]). Thus, genetic factors control the
induction of measles antibodies in 12-month-old infants, which
suggests that the influence of environmental determinants on
anti-TT and total IgG responses at age 12 months does not reflect
the age of the child at time of sampling but, rather, the time
since immunization.
Predominant role of environmental factors in the avidity
maturation of anti-TT antibodies. We next assessed the re-
spective roles of genetic and environmental factors in the avidity
maturation of anti-TT antibodies. Protection against tetanus
toxin, as assessed by in vitro tests, correlates with the recognition
of the toxin-binding site, with a striking influence of antibody
affinity. Thus, the maturation of antitoxin responses is essential
to reach the affinity threshold that is required for effective toxin
neutralization [36]. Figure 1 (middle and bottom) shows the geo-
metric mean AI and % HA for anti-TT antibodies measured at
ages 5 and 12 months in a subgroup of 135 MZ and DZ twin
pairs from whom sufficient serum was available. Anti-TT AI and
% HA antibodies significantly increased between ages 5 and 12
months, demonstrating efficient avidity maturation. This avidity
maturation process was similar in MZ and DZ twin pairs (table
3). Correlations of AI and % HA antibodies measured at ages 5
and 12 months were similar within MZ and DZ twin pairs,
resulting in no significant heritability (table 4). The final model
for the 12-month AI data included only common and unique
environmental factors. Similar estimates of heritability of AI at
age 12 months were obtained using the ACE model (table 4).
Thus, environmental factors play a predominant role in the con-
trol of anti-TT avidity maturation in infants.
DISCUSSION
Immune responses are complex traits influenced by genetic and
environmental factors. We previously reported that genetic de-
terminants play a central role in the control of early primary
IgG responses to vaccines in young infants [27]. In the present
article, we show that the relative role of environmental deter-
minants predominates during the late phase of IgG responses.
The persistence and avidity maturation of TT-specific anti-
bodies in Gambian infants is driven by the late development
of the primary immune response and/or by exposure to non–
TT-specific factors [28]. Whereas significant heritability of IgG
responses to TT was detected in 5-month-old infants immu-
nized at ages 2, 3, and 4 months, we observed that environmental
factors predominantly controlled anti-TT IgG levels in infants
12 months old. Although this analysis could not be extended to
Memory Vaccine Responses in Infants • JID 2006:193 (1 June) • 1603
other vaccine antigens, a similar difference was observed with
total IgG levels: genetic factors control total IgG titers at age 5
months, whereas environmental factors play a predominant role
in the responses to nonvaccine antigens at age 12 months. Unlike
exposure to TT, exposure to nonvaccine antigens cannot be con-
trolled, and we cannot formally exclude the possibility that the
reduction in the heritability of total IgG levels is partly related
to an increased discordance of exposure within twin pairs. How-
ever, this possibility is not supported by the fact that twins were
raised together for the duration of the study and by the high
and identical correlations of total IgG levels measured in MZ
and DZ twin pairs at age 12 months (table 2), which indicates
an important role of environmental factors.
To our knowledge, this is the first longitudinal study of the
determinants of IgG responses in humans. Previously published
twin studies of vaccine responses were cross-sectional and there-
fore could not evaluate the determinants of antibody persistence
[30, 37, 38]. The predominant role of environmental determi-
nants in anti-TT responses observed at age 12 months could have
been related to the increasing age of the infants or to the time
since immunization. The observation that the early IgG response
to measles vaccine is predominantly controlled by genetic de-
terminants confirmed that the influence of environmental factors
on anti-TT responses at age 12 months reflects the time since
immunization. This suggests that distinct factors influence the
early-effector and late-memory phases of IgG responses. Among
the factors that could be particularly important in the control
of early antibody responses are innate immune response genes.
The observation that genetic factors play a predominant role
in the control of antibody response to measles vaccine is in
keeping with data reported by Tan et al. [30]. The identification
of the genes involved may help in the development of more-
effective measles vaccines inducing higher early antibody re-
sponses [27]. The role of genetic factors in the control of anti-
measles antibody persistence and avidity maturation should be
examined.
The mechanisms leading to the persistence of antigen-spe-
cific antibodies are not fully understood. The postimmuniza-
tion period is characterized by a rapid decrease in antibody
levels that presumably reflects the interruption of antibody pro-
duction by short-lived antibody-secreting cells. This is followed
by a second period, during which antigen-specific antibody
levels decrease with slower kinetics. The antibody persistence
could result from long-lived plasma cells having reached ap-
propriate survival niches within the bone marrow [39–41]. Al-
ternatively, antibody production may be sustained by antigen-
specific or bystander reactivation of memory B cells [42, 43].
A number of environmental factors could influence the per-
sistence of IgG vaccine responses in infants. It is tempting to
postulate that exposure to microorganisms plays an important
role. Between ages 5 and 12 months, maternal antibodies dis-
appear, and infants are exposed to a large number of micro-
organisms. These microorganisms could either favor antibody
persistence through the bystander activation of memory B cells
or favor antibody decline by inducing the differentiation of
plasma cells competing for a restricted number of niches within
the bone marrow. We cannot exclude that this influence would
be more marked in tropical environments. For example, Plas-
modium falciparum malaria drives immunoglobulin production
to high levels, results in a more-rapid turnover of IgG in Gam-
bian adults, and may diminish the persistence of meningococcal
vaccine antibodies [14, 44–47]. However, immune responses
to TT vaccine are robust even in malaria-infected African chil-
dren [48], and the shorter duration of infant antibody responses,
compared with those in adults, has been observed worldwide
[10–12, 14, 49, 50].
In the present study, we also demonstrate that the induction
of high-avidity antibodies to TT takes place within a few months
after early infant immunization. The detection of high-avidity
antibody responses to infant TT immunization are in keeping
with our previously published results showing adult-like pro-
cesses of avidity maturation to TT and other protein antigens
in infant mice [23]. These data also complement studies that
have indicated that high-avidity antibody responses can be in-
duced by glycoconjugate vaccines in human infants [19, 20, 22,
24]. Thus, the lower affinity of antibodies measured after infant
rotavirus [21] or N. meningitidis [20] infections, compared with
those after adult infections, is likely to reflect differences in the
time since first exposure rather than an impaired somatic mu-
tation/antigen-driven B cell selection process. The affinity mat-
uration process of TT-specific antibodies during the first year
of life is essentially controlled by nongenetic factors. This could
be the consequence of several different mechanisms. Somatic
hypermutation is a random phenomenon and, as such, could
lead to the generation of a diversity of centrocyte populations
that is not primarily programmed by genetic determinants. In
addition, the selection of centrocytes producing high-affinity
antibodies is mediated by their interactions with follicular den-
dritic cells (FDCs) bearing antigens and with helper CD4+ fol-
licular T lymphocytes [51]. Microbial antigens could either
promote the production of high-affinity antibodies by com-
peting at the level of FDCs for presentation to centrocytes or
favor the production of low-affinity antibodies through the
bystander activation of centrocytes. Although significant pos-
itive correlations were observed between the % HA anti-TT
antibodies and total IgG levels at age 12 months ( [95%rp 0.14
CI, 0.02–0.27]; ), in accordance with the hypothesis ofPp .02
a positive competitive influence at the FDC level, further studies
will be required to explore this hypothesis and to eventually
identify the environmental factors involved. This represents a
novel and important objective for the improvement of vaccine
efficacy in young children.
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